Policy "combo" has been launched to make more anticancer drugs benefit cancer patients

The incidence rate and mortality rate of cancer in China has been increasing in recent years According to statistics, there are more than 14 million new cancer cases every year in the world, and 4.29 million new cases every year in China, accounting for 30% of the new cancer cases in the world The life of cancer patients needs anti-cancer drugs to continue However, anti-cancer drugs are comparable to "high-priced drugs" A drug or a needle of medicine needs tens of thousands or even hundreds of thousands of yuan, which brings heavy burden to the families of patients Last July's excellent work "I'm not the God of medicine" also pointed out that anti-cancer drugs are expensive and most patients can't afford to use them In order to solve this problem, a series of policies have been launched in China to make more cancer patients have access to and can afford anticancer drugs The cost of anticancer drugs is mainly due to high research and development costs and large investment Data shows that in recent years, the success rate of research and development of new anti-cancer drugs is less than 2%, and the average cost is more than $700 million Only high pricing can enterprises recover the initial investment In order to help the cost burden of anticancer drug R & D enterprises, from May 1, 2018, general VAT taxpayers can choose to pay VAT according to the simple method and the 3% collection rate for the production, sale, wholesale and retail of anticancer drugs At the same time, the import tariff of 28 kinds of drugs, including anti-cancer drugs, will be reduced from the original 3% - 6% to zero, so that patients will benefit more A total of 103 anticancer drug preparations and 51 anticancer drug raw materials are included in the list of anticancer drugs with reduced value-added tax The reduction of tax rate will bring "red envelop rain" to the research and development enterprises of anticancer drugs, increase more profits, relieve the pressure of high investment cost of research and development of enterprises, and also reduce the drug price to a certain extent, benefiting more patients For example, Jingfeng pharmaceutical has 6 anti-cancer drugs shortlisted for value-added tax reduction According to the financial director, for drugs with a price of 100 yuan, 16% of the value-added tax policy enterprises recognize the revenue of 86.21 yuan, and now they can recognize the revenue of 97.09 yuan, with an increase of 12.62% This policy will increase the gross profit of the company to varying degrees In addition to the implementation of zero tariff and tax reduction for imported anti-cancer drugs, China has also introduced a series of combination boxing For example, on October 10, 2018, the national health insurance bureau announced that 17 kinds of anticancer drugs will be included in the medical insurance, and most of the payment standards after the negotiation of imported drugs are lower than the market prices of surrounding countries or regions, further reducing the drug burden of cancer patients in China   In 2019, China will further increase the support of cancer prevention and treatment drugs, for example, 12 kinds of new anti-tumor drugs urgently needed in clinic will be included in the national essential drugs catalogue 2018, including innovative drugs such as small molecule targeted drugs; after the pilot procurement in volume, 25 selected products will start to reduce prices by a large margin, with an average price reduction of 52%, and the price of anti-cancer drugs will reach 95%; on August 20, 2019 version of national medicine According to the publication of the general catalog, some drugs for treatment of major diseases such as cancer and rare diseases have entered the list to be negotiated and entered the catalog after negotiation The new version of the catalogue will be officially implemented on January 1, 2020 Under the stimulation of huge market demand, China's cancer drug market will continue to expand According to the 2018-2023 China anticancer drug market prospect survey and investment opportunity research report released by China Business Industry Research Institute, the market scale of China's anticancer drugs in 2016 is up to 112.2 billion yuan, and it is expected to exceed 200 billion yuan in 2022 In this context, more and more domestic enterprises join in the research and development of innovative drugs such as anti-tumor drugs For example, Hengrui pharmaceutical, Fosun Pharmaceutical, Beida pharmaceutical, Kelun pharmaceutical, Shiyao group, Shanghai pharmaceutical, etc., and some pharmaceutical companies have made some breakthroughs in anti-cancer drugs In general, China's anticancer drug market has a good prospect, but the research and development capacity of China's anticancer drugs is weak, and the road of research and development is long With more anti-cancer drugs coming in the future, it will further benefit cancer patients in China and reduce the burden of drug use!